New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies

Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).

Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key molecular pathways that could be targeted to treat this cardiopulmonary disorder. A multitude of new therapies with differing mechanisms of action began to appear in the late 1990s and experts discovered that combination treatments were key to extending life. Today, 5-year survival rates approach 70%.  

Premiere clinical guidelines on diagnosing and managing PAH were recently revised and updated and in March 2024, two new treatment choices were approved by the FDA " a fixed-dose, single-tablet combination of the two drug classes that are recommended as initial treatment for most patients, and a first-in-class transforming growth factor inhibitor.

Join PAH expert Dr. John J. Ryan for this on-demand data dive activity that explores recent guideline changes, newly approved treatments, and freshly released data on emerging therapies.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

Assess new and revised recommendations for the management of PAH outlined in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
Integrate investigational treatments (when available) into PAH treatment selections based on recently released or forthcoming clinical trial findings